IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event
MOUNTAIN VIEW, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a panel discussion on bispecific therapies at the Canaccord Genuity Horizons in Oncology Virtual Event on Wednesday, April 8 at 10:15 a.m. ET.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at /news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact:
Argot Partners
David Pitts
212-600-1902
